Description: PTC Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of orally administered and proprietary small-molecule drugs for patients living with serious and life-threatening conditions, including genetic and neuromuscular disorders, cancer, and infectious diseases. Its approach includes post-transcriptional control, RNA biology, and gene expression modulation by small-molecules. The company has strategic alliances with AstraZeneca; Celgene Corporation; Cystic Fibrosis Foundation; Genzyme Corporation; Gilead; Muscular Dystrophy Association; Merck & Co., Inc.; Parent Project Muscular Dystrophy; Pfizer Inc.; Roche; Spinal Muscular Atrophy Foundation; and Wellcome Trust. PTC Therapeutics, Inc. was founded in 1998 and is based in South Plainfield, New Jersey.
Home Page: www.ptcbio.com
PTCT Technical Analysis
100 Corporate Court
South Plainfield,
NJ
07080
United States
Phone:
908 222 7000
Officers
| Name | Title |
|---|---|
| Dr. Stuart W. Peltz Ph.D. | Co-Founder, CEO & Exec. Director |
| Dr. Allan Steven Jacobson Ph.D. | Co-Founder, Chairman of Scientific Advisory Board & Independent Director |
| Ms. Emily Luisa Hill | Chief Financial Officer |
| Dr. Neil Almstead Ph.D. | Chief Technical Operations Officer |
| Mr. Mark Elliott Boulding | Exec. VP & Chief Legal Officer |
| Mr. Eric Pauwels | Chief Bus. Officer |
| Ms. Dawn A. Svoronos | Advisor |
| Dr. Matthew B. Klein F.A.C.S., FACS, M.D., M.S., MS | Chief Operating Officer |
| Ms. Christine Utter | Sr. VP, Chief Accounting Officer & Head of People Services |
| Ms. Ellen Welch Ph.D. | Chief Scientific Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1743.2734 |
| Price-to-Sales TTM: | 4.0332 |
| IPO Date: | 2013-06-20 |
| Fiscal Year End: | December |
| Full Time Employees: | 1167 |